|Videos|January 25, 2017

Ibrutinib Yields Response in Patients With Chronic GVHD

This video examines a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

Chronic graft vs host disease (GVHD) is a serious complication of allogeneic stem cell transplantation, and among patients who fail corticosteroids there remains an unmet need for an effective therapy.

In this video, Lori Styles, MD, medical director of Pharmacyclics in Sunnyvale, California, discusses a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

Results of the trial (abstract LBA-3) were presented at the 58^th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.

November 5th, 2026

FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC

Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

November 5th, 2026

Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.

November 5th, 2026

FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC

The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.

November 5th, 2026

Evaluating Factors That Affect HDR Brachytherapy and SBRT Decisions in Radiation Oncology

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.